Results 21 to 30 of about 21,696 (215)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis [PDF]

, 2021
As the first FDA-approved tyrosine kinase inhibitor for treatment of patients with myelofibrosis (MF), ruxolitinib improves clinical symptoms but does not lead to eradication of the disease or significant reduction of the mutated allele burden.
Mark Robinson, Dragana Milojkovic, Avirup Chowdhury, Alistair G. Reid, Simone Claudiani, Jane F. Apperley, Cristina Pellegrini, Carme R. Fiol, Katya Mokretar, Michael W. Deininger, Antinisca Di Marco, Kikkeri Naresh, Michael Albert, Jamshid S. Khorashad, Clinton C. Mason, Andrea Bianchi, Kanagaraju Ponnusamy   +16 more
core   +3 more sources

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Frontiers in Oncology, 2021
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but ...
Yingxin Sun, Yingxin Sun, Yifeng Cai, Jia Chen, Jia Chen, Jiannong Cen, Jiannong Cen, Mingqing Zhu, Mingqing Zhu, Jinlan Pan, Jinlan Pan, Depei Wu, Depei Wu, Aining Sun, Aining Sun, Suning Chen, Suning Chen   +16 more
doaj   +1 more source

JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

Clinical & Translational Immunology, 2023
Objectives Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT).
Yigeng Cao, Jiali Wang, Shan Jiang, Mengnan Lyu, Fei Zhao, Jia Liu, Mingyang Wang, Xiaolei Pei, Weihua Zhai, Xiaoming Feng, Sizhou Feng, Mingzhe Han, Yuanfu Xu, Erlie Jiang   +13 more
doaj   +1 more source

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2022
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary complication of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we retrospectively identified seven patients
Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, Yuanyuan Shi, Lining Zhang, Mengze Hao, Fei Zhao, Rongli Zhang, Jialin Wei, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han   +12 more
doaj   +1 more source

Ruxolitinib en COVID-19 grave [PDF]

, 2021
Introducción: La morbimortalidad por COVID-19 se asocia principalmente con el síndrome respiratorio agudo severo (SARS), relacionado con una respuesta inmunitaria aumentada del huésped con aumento de los niveles circulantes de citoquinas.
Iastrebner, Marcelo, Estefanía Minoldo, María Celia Cuesta, Minoldo, Estefanía, Verde, Gabriel, Pablo Gutiérrez Fernández, Lettieri, Carolina, Carolina Lettieri, Mandrile, Araceli, Gabriel Verde, Araceli Mandrile, García Espina, Edgardo, Sebastián Gervasoni, Silvio Payaslian, Contreras, Angela Paola, Caruso, Vanesa, Gervasoni, Sebastián, Gutiérrez Fernández, Pablo, Vanesa Caruso, Angela Paola Contreras, Cuesta, María Celia, Cayetano Galetti, Marcelo Iastrebner, Galetti, Cayetano, Payaslian, Silvio, Edgardo García Espina, Castro, Joaquín, Joaquín Castro   +27 more
core   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults

, 2022
Despite repeated malaria infection, individuals living in malaria endemic areas remain vulnerable to re-infection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when ...
El Gaaloul, Myriam, Kress, Anita, Wells, Timothy, van Giersbergen, Paul, McCarthy, James S, Barnes, Karen I, Abla, Nada, Chughlay, M Farouk, Griffin, Paul, Schultz, Hayley B, Tapley, Peter, Möhrle, Jörg J, Engwerda, Christian R., Reuter, Stephanie E, et al., Webster, Rebecca A   +15 more
core   +1 more source

Management of myelofibrosis after ruxolitinib failure [PDF]

, 2020
Contains fulltext : 220684.pdf (Publisher’s version ) (Open Access)Myelofibrosis is a BCR-ABL1-negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis ...
Mesa, R.A., Harrison, C.N., Schaap, N.P.
core   +1 more source

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Frontiers in Endocrinology, 2023
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose
Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher   +3 more
doaj   +1 more source

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica, 2015
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo ...
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop Kantarjian   +21 more
doaj   +1 more source